Entrectinib can induce nerve cell damage by inhibiting PI3K-AKT and TGF-β signaling pathways

BackgroundThe tyrosine receptor kinase inhibitor (TRKi) entrectinib is used to treat neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors and ROS1-positive patients. Despite its impressive efficacy against cancer, the clinical application is still limited by the central nervous...

詳細記述

書誌詳細

主要な著者:	Qingshan Tang, Jiachen Dong, Feng Zhang, Dan Zhao, Qi Yang, Jiayu Wen, Yuhao Sun, Jifu Wei, Zhixian Liu
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2025-02-01
シリーズ:	Frontiers in Pharmacology
主題:	entrectinib nerve cell damage THBS1 Pi3k-akt TGF-β
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1489210/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!